Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Tue, 05.01.2021
PNE AG
DGAP-Media / 05.01.2021 / 10:29
Press release
PNE AG has brokered further power purchase agreements (PPA) for operators
Cuxhaven, January 5, 2021 - PNE AG has again further expanded its positioning in the brokerage business of power purchase agreements (PPAs) in 2020. With an additional volume of around 300 gigawatt hours (GWh), PNE was ab [ … ]
Tue, 05.01.2021
Atriva Therapeutics GmbH
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin
- RESPIRE is a placebo-controlled, international, multi-center trial treating hospitalized patients with moderate to severe COVID-19
- The Phase II clinical trial will evaluate efficacy, safety and pharmacokinetics [ … ]
Tue, 05.01.2021
Nouveau Monde Graphite
MONTRÉAL, QUÉBEC, January 5, 2020 - Nouveau Monde Graphite Inc. ("Nouveau Monde" or the "Company") (TSX.V: NOU; OTCQX: NMGRF; Frankfurt: NM9) is starting 2021 with momentum after a remarkably productive fall season. The Company expects to obtain governmental authorization for its Matawinie graphite project early in Q1, enabling the construction of [ … ]
Tue, 05.01.2021
ViGeneron GmbH
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
- Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
- The companies will use ViGeneron's proprietary vgAAV technology to efficiently transduce target cells via intravi [ … ]
Tue, 05.01.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
- The Swissmedic MAA seeks approval for tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
PLANEGG/MUNICH, Germany and MORGES, Switz [ … ]
Tue, 05.01.2021
Evotec SE
ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS PAYMENT TO EVOTEC
Hamburg, Germany, 05 January 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies' iPSC-based neuroscience par [ … ]
Tue, 05.01.2021
Polyphor AG
Allschwil, Switzerland, January 5, 2021
Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Co [ … ]
Tue, 05.01.2021
Implenia AG
Implenia, together with project partner HOCHTIEF, has been awarded the contract to build the 2.2-kilometre-long Altona noise protection tunnel on the A7 motorway in Hamburg. The net contract is worth a total of around EUR 580 million. Implenia will take the commercial lead on the project, working as part of a joint venture in which HOCHTIEF has the [ … ]
Tue, 05.01.2021
ENCAVIS AG
Corporate NewsENCAVIS already connected the second major project in Spain "Talayuela" to the grid on schedule
Hamburg, January 5, 2021 - SDAX-listed wind and solar park operator Encavis AG (Prime Standard, ISIN: DE0006095003, Stock Exchange Initial: ECV), injected the first kilowatt hours (kwh) into the Spanish high voltage grid from "Talayuela", [ … ]
Tue, 05.01.2021
GRENKE AG
GRENKE generates new leasing business in the 2020 financial year equal to 71.2% of the previous year's level
- GRENKE Group Leasing's new business in the 2020 financial year amounts to EUR 2,027.9 million, equal to 71.2% of the level in the 2019 financial year
- GRENKE Group Leasing's new leasing business in Q4 2020 reaches EUR 426.7 million, eq [ … ]